



(51) International Patent Classification:

A61K 31/427 (2006.01) C07D 401/12 (2006.01)

A61K 31/496 (2006.01) C07D 417/12 (2006.01)

(21) International Application Number:

PCT/US2020/066211

(22) International Filing Date:

18 December 2020 (18.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/951,464 20 December 2019 (20.12.2019) US

62/951,467 20 December 2019 (20.12.2019) US

(71) Applicant: C4 THERAPEUTICS, INC. [US/US]; 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US).

(72) Inventors: NASVESCHUK, Christopher G.; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). DUPLESSIS, Martin; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). AHN, Jae Young; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). HIRD, Alexander W.; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). MICHAEL, Ryan E.; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). LAZARSKI, Kiel; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). LIANG, Yanke; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). JAESCHKE, Georg; c/o F. Hoffman-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). RICCI, Antonio; c/o F. Hoffman-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). GOERGLER, Annick; c/o F. Hoffman-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). RUEHER, Daniel; c/o F. Hoffman-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH).

(74) Agent: BELLOWS, Brent R. et al.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR

(57) Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.



WO 2021/127561 A1